- Home
- CVAC vs TCPC Comparison
CVAC vs TCPC Comparison
Compare CVAC & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- TCPC
- Stock Information
- Founded
- CVAC 2000
- TCPC 2006
- Country
- CVAC Germany
- TCPC United States
- Employees
- CVAC N/A
- TCPC N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- TCPC Finance/Investors Services
- Sector
- CVAC Health Care
- TCPC Finance
- Exchange
- CVAC Nasdaq
- TCPC Nasdaq
- Market Cap
- CVAC 764.4M
- TCPC 648.0M
- IPO Year
- CVAC 2020
- TCPC 2012
- Fundamental
- Price
- CVAC $4.47
- TCPC $7.84
- Analyst Decision
- CVAC Strong Buy
- TCPC Hold
- Analyst Count
- CVAC 2
- TCPC 4
- Target Price
- CVAC $14.00
- TCPC $7.50
- AVG Volume (30 Days)
- CVAC 779.9K
- TCPC 597.2K
- Earning Date
- CVAC 05-20-2025
- TCPC 05-08-2025
- Dividend Yield
- CVAC N/A
- TCPC 17.35%
- EPS Growth
- CVAC N/A
- TCPC N/A
- EPS
- CVAC 0.87
- TCPC N/A
- Revenue
- CVAC $566,039,775.00
- TCPC $259,596,996.00
- Revenue This Year
- CVAC N/A
- TCPC N/A
- Revenue Next Year
- CVAC $37.79
- TCPC N/A
- P/E Ratio
- CVAC $5.16
- TCPC N/A
- Revenue Growth
- CVAC 787.60
- TCPC 20.88
- 52 Week Low
- CVAC $2.37
- TCPC $6.27
- 52 Week High
- CVAC $5.28
- TCPC $11.52
- Technical
- Relative Strength Index (RSI)
- CVAC 65.61
- TCPC 62.34
- Support Level
- CVAC $3.35
- TCPC $7.79
- Resistance Level
- CVAC $4.80
- TCPC $7.89
- Average True Range (ATR)
- CVAC 0.30
- TCPC 0.17
- MACD
- CVAC 0.07
- TCPC 0.04
- Stochastic Oscillator
- CVAC 77.51
- TCPC 91.38
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About TCPC BlackRock TCP Capital Corp.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.